Testing a new kidney disease treatment for children alongside standard therapy

This trial is testing a new medication called finerenone in children ages 6 months to 18 years who have chronic kidney disease and are losing protein in their urine. The medication is designed to work together with medicines your child may already be taking (called ACE inhibitors or ARBs) to better protect the kidneys and reduce protein loss. Researchers want to see if this medication works better than a placebo (a pill with no medicine) when added to your child's current treatment.

Children with chronic kidney disease often lose too much protein in their urine, which can damage their kidneys further. While current standard treatments help, they don't work well enough for all children. This trial exists to see if the new treatment can offer better protection for growing kidneys by working in a different way than medicines already available.